Dr. Jan Ehlers, chief executive officer at Secop GmbH, shares the trends and challenges in the cold chain industry and the rising demand for vaccine transport solutions.
Key insights:
- The recent surge in the industry requiring reliable, ultra-low temperature medical cold chain solutions is due to the rise in mRNA technology adoption and Cell & Gene Therapy (CGT).
- The demand for effective and efficient last mile delivery of new generation vaccines is challenging the medical cold chain for reliable and robust solutions.
- Secop developed an innovative ultra-low temperature (ULT) cooling box, which is optimised for the last mile of distribution.
Whilst the need for refrigeration or ultra-low temperature storage for vaccines is not new, demand increased considerably during the pandemic meaning the cold chain industry had to rapidly scale up production. The recent surge in the industry requiring reliable, ultra-low temperature medical cold chain solutions, is down to factors such as the rise in adoption of mRNA technology and the growing prominence of Cell & Gene Therapy (CGT). With this rise, we have seen increased support from the government for research activities and clinical trials focusing on immunisation, in turn increasing demand for vaccine transport carriers further.